Volume 21, Number 6—June 2015
Research
Risk Factors for Acquisition of Drug Resistance during Multidrug-Resistant Tuberculosis Treatment, Arkhangelsk Oblast, Russia, 2005–2010
Sarah E. Smith
, Julia Ershova, Natalia Vlasova, Elena Nikishova, Irina Tarasova, Platon Eliseev, Andrey Maryandyshev, Igor G. Shemyakin, Ekaterina V. Kurbatova, and J. Peter Cegielski
, Julia Ershova, Natalia Vlasova, Elena Nikishova, Irina Tarasova, Platon Eliseev, Andrey Maryandyshev, Igor G. Shemyakin, Ekaterina V. Kurbatova, and J. Peter Cegielski
Table 1
Drug susceptibility and acquired resistance of Mycobacterium tuberculosis from 171 patients with MDR TB, Arkhangelsk Oblast, Russia, 2005–2010*
| Drug(s) tested | Baseline, no. (%) |
Acquired resistance no. (% of susceptible) | |
|---|---|---|---|
| Resistant | Susceptible | ||
| RIF | 167 (97.7) | 4 (2.3) | 1 (25.0) |
| INH | 170 (99.4) | 1 (0.6) | 0 |
| MDR TB drugs† | 167 (97.7) | 4 (2.3) | 1 (25.0) |
| EMB | 135 (79.0) | 36 (21.0) | 2 (5.6) |
| STR | 163 (95.3) | 8 (4.7) | 1 (12.5) |
| All 4 first-line drugs‡ | 130 (76.0) | 41 (24.0) | 3 (7.3) |
| KAN | 72 (42.1) | 99 (57.9) | 4 (4.0) |
| AMK | 30 (17.5) | 141 (82.5) | 1 (0.7) |
| CAP | 13 (7.6) | 158 (92.4) | 3 (1.9) |
| Any second-line injectable§ | 74 (43.3) | 97 (56.7) | Not applicable |
| All 3 second-line injectables | 10 (5.8) | 161 (94.2) | 7 (4.4) |
| OFX | 10 (5.8) | 161 (94.2) | 6 (3.7) |
| XDR TB drugs¶ | 7 (4.1) | 164 (95.9) | 4 (2.4) |
| ETA | 46 (26.9) | 125 (73.1) | 6 (4.8) |
| PAS | 54 (31.6) | 117 (68.4) | 2 (1.7) |
| Both second-line companion drugs | 18 (10.5) | 153 (89.5) | 6 (3.9) |
| All second-line drugs | 1 (0.6) | 170 (99.4) | 14 (8.2) |
| All drugs | 1 (0.6) | 170 (99.4) | 16 (9.4) |
*AMK, amikacin; CAP, capreomycin; EMB, ethambutol; ETA, ethionamide; FQ, fluoroquinolone; INH, isoniazid; KAN, kanamycin; OFX, ofloxacin; MDR TB, multidrug-resistant tuberculosis; RIF, rifampin; STR, streptomycin; PAS, para-aminosalicylic acid; XDR, extensively drug-resistant tuberculosis.
†RIF and INH.
‡RIF, INH, EMB, and STR.
§KAN,AMK, and CAP.
¶RIF, INH, a second-line injectable drug, and an FQ.
Page created: May 15, 2015
Page updated: May 15, 2015
Page reviewed: May 15, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.